Disease: Parkinson's disease
Type of study: Interventional trial
Coordinating investigator: Brage Brakedal
Study director: Charalampos Tzoulis
Background: Parkinson’s disease (PD) is a major cause of death and disability and has a devastating global socioeconomic impact. Available treatments are purely symptomatic and there is an urgent need for disease-modifying therapies. Previous research by Neuro-SysMed and others suggests that nicotinamide adenine dinucleotide (NAD) replenishment therapy may be neuroprotective in PD and delay neurodegeneration and clinical disease progression. Encouraged by these findings, we are conducting NOPARK, a phase II double-blinded randomised clinical trial of oral NR in early PD.
The primary objective of the NOPARK study is to determine whether a high dose of oral NR delays disease progression in PD measured by the change in total MDS-UPDRS.
Design: NOPARK is a phase III double-blinded randomised clinical trial of oral NR, 1000 mg per day, in early PD. NOPARK will recruit a total of 400 patients with early-stage PD (within two years from diagnosis) from 10 centres across Norway. Study duration will be one year.
Primary endpoint: The between-group (NR vs. placebo) difference of the change in the total MDS-UPDRS score between baseline and end of study (week 52).
Status: The study is fully enrolled and will be concluded in June 2025.
Participating centres
- Haukeland University Hospital, Bergen
- Akershus University Hospital, Lørenskog
- Oslo University Hospital, Oslo
- Vestre Viken Hospital, Drammen
- Østfold Hospital, Kalnes
- Nordland Hospital, Bodø
- University Hospital of North Norway, Tromsø
- Førde Hospital, Førde
- Dr. Karen Herlofson, Arendal
- Sørlandet Hospital Arendal
- Haugesund Hospital, Haugesund
- Molde Hospital, Molde
Funding
- KLINBEFORSK
- The Regional Health Authority of Western Norway
- The Research Council of Norway, Neuro-SysMed
- Haukeland University Hospital
- Participating hospitals